NEW BRUNSWICK, N.J. / May 08, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12th, at the Loews Miami Beach Hotel, Miami Beach, Florida. Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine and John Reed, Executive Vice President, Innovative Medicine R&D will represent the Company in a session scheduled at 2:00 pm (Eastern Time).
This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.
The audio webcast replay will be available approximately 48-hrs after the webcast.
| Last Trade: | US$211.58 |
| Daily Change: | 1.57 0.75 |
| Daily Volume: | 6,401,758 |
| Market Cap: | US$509.910B |
December 06, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
